



Published in final edited form as:

Alzheimers Dement. 2014 November ; 10(6): 704–712. doi:10.1016/j.jalz.2013.11.009.

Extension and refinement of the predictive value of different classes of markers in ADNI: Four year follow-up data

Jesus J Gomar^{a,b}, Concepcion Conejero-Goldberg, MD, PhD^a, Peter Davies, PhD^{a,c}, and Terry E Goldberg, PhD^{a,c,*} for the Alzheimer's Disease Neuroimaging Initiative (ADNI)¹

^aThe Litwin-Zucker Research Center, The Feinstein Institute for Medical Research, Manhasset, NY, USA

^bFIDMAG, Hermanas Hospitalarias, Sant Boi de Llobregat, Spain

^cHofstra North Shore LIJ School of Medicine, Hempstead, NY, USA

Abstract

Background—This study examined the predictive value of different classes of markers in the progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) over an extended 4 year follow-up in ADNI.

Methods—MCI patients assessed on clinical, cognitive, MRI, PET-FDG, and CSF markers at baseline, and followed on a yearly basis for four years to ascertain progression to AD. Logistic regression models were fitted in clusters including demographics, APOE genotype, cognitive markers, and biomarkers (morphometric, PET-FDG, CSF Abeta and tau).

Results—The predictive model at four years revealed that two cognitive measures, an episodic memory measure and a clock drawing screening test, were the best predictors of conversion (AUC= 0.78).

Conclusions—This model of prediction is consistent to the previous model at two years, thus highlighting the importance of cognitive measures in progression from MCI to AD. Cognitive markers were more robust predictors than biomarkers.

Keywords

Mild Cognitive Impairment; Alzheimer's disease; cognition; MRI; FDG-PET; CSF

© 2014 Elsevier Inc. All rights reserved.

*Corresponding author and request for reprints: Terry E. Goldberg, 350 Community Drive, Manhasset, NY 11030, USA. Telephone: 516-562- 0410. Fax: 516-562-0401. tgoldber@nshs.edu.

¹Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Conflicts

Dr. Gomar reports no biomedical financial interests or potential conflicts of interest. Dr. Conejero-Goldberg reports no biomedical financial interests or potential conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

The prevalence of dementia is approximately 24.3 million people worldwide, with predictions that this amount will be doubled every 20 years [1]. Among the causes of dementia, Alzheimer's disease (AD) is the most common. AD dementia is currently considered as an end state after consistent pathologic brain changes have accumulated, perhaps years before earliest clinical symptoms manifest.

Relatively few studies have directly compared the differential contribution of different kind of markers (biomarkers and cognitive markers) in their predictive utility for the conversion from Mild Cognitive Impairment (MCI) to AD. This motivated us to undertake a systematic and comprehensive examination of several classes of markers. In a previous study, we found that a combination of delayed verbal episodic memory measures and a middle temporal lobe cortical thickness measure were the strongest predictive factors of the conversion to AD from MCI in a follow-up period of two years, using a sample from the Alzheimer's disease Neuroimaging Initiative (ADNI) [2].

Since our initial report, several studies investigating combination of different markers, have obtained similar findings. Ewers et al [3] found that memory measures (free recall) and executive function measures had comparable predictive accuracy to that of biomarkers within ADNI database, using an approach involving a cross-validation paradigm to differentiate AD from elderly control subjects that was later applied to the prediction of MCI conversion to AD. Heister et al found that MCI patients with combination of both, learning impairment and increased hippocampal atrophy, as having highest risk of conversion to AD [4]. Jedynak et al [5], using advanced statistical methods, found that inflection of a delayed memory measure preceded that of other biomarkers (CSF levels and hippocampal volumes) on the progression from MCI to AD in the ADNI database. This set of findings was recently the subject of an editorial that highlighted the otherwise often undervalued importance of cognitive measures as early markers of AD progression [6].

In this study, the first aim was to derive a model for prediction and contrast it with our prior model findings, but here over a longer follow-up period of four years in the ADNI database. Given the often undervalued but widespread phenomenon of failure-to-replicate in published biomedical research [7, 8], we believe that confirming the validity of a model of prediction for the transition from MCI to AD is of great value, as well as it contributes to clarify the processes of this transition.

We appreciate that this is not a replication in a separate and independent sample. Nevertheless, as an extension and refinement of our results, we think that this approach will be a step toward validation of our overarching findings (that cognitive measures were robust predictors of conversion from MCI to AD).

We hypothesized that measures of episodic memory and brain morphometric measures will still be predictive of the development of AD in a longer follow-up. To further test this hypothesis we also included new biomarkers that we did not evaluate in our previous work: 1) a recently proposed factor that has been implicated in the risk of AD development,

namely CSF linear combination of $A\beta_{1-42}$ and $p\text{-tau}_{181p}$ [9]; 2) fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers, specifically the hypometabolic convergence index (HCI), a single measure intended to reflect the extent to which the pattern and magnitude of cerebral hypometabolism in an individual correspond to that in probable AD patients [10]; this measure has been shown to be predictive of AD progression in MCI alone or in combination with hippocampal volume.

2. Methods

2.1. Participants

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI). Data were downloaded on April 18th 2012.

In the present study, we restricted our analyses to the MCI subjects recruited by ADNI-1 followed for a period of 4 years. Furthermore, we also sought to extend our model, including a recently proposed model of the combination of AB and p-tau for the prediction of conversion, within the same analytic framework that we utilized in our previous study. Inclusion criteria for MCI and healthy subjects are described elsewhere [2] and in the ADNI website (<http://www.adni-infor.org>). Briefly, MCI patients had Mini-Mental State Exam (MMSE) [11] scores between 24 and 30 (inclusive), a memory complaint, objective memory loss, a Clinical Dementia Rating (CDR) [12] score of 0.5, absence of significant impairment in other cognitive domains, and preserved activities of daily living. In an attempt to ascertain conversion to AD, we excluded MCI subjects whose conversion to AD was not verified at another additional follow-up (i.e. at least two visits being diagnosed as MCI). In addition, if MCI patients converted to AD, and AD status did not remain at one further follow-up, subjects were also excluded from analysis. All participants signed written informed consent for participation in the ADNI, as approved by the institutional board at each participating center.

2.2. Procedures

2.2.1. CSF Measures—Details of acquisition are available at ADNI webpage and upon request of the authors. Concentrations of $A\beta_{1-42}$, t-tau and $p\text{-tau}_{181p}$ in CSF have been reported as strongly associated with development of AD [13], and accurate in identifying incipient AD [14]. We utilized log transformed values for $A\beta_{1-42}$, t-tau and $p\text{-tau}_{181p}$, as well as for t-tau/ $A\beta_{1-42}$, $p\text{-tau}_{181p}/A\beta_{1-42}$, and $A\beta_{1-42}/p\text{-tau}_{181p}$ ratios. Since some reports have indicated that $A\beta_{1-42}$ influence on brain volumetric and cognitive decline measures only occurs in the presence of elevated $p\text{-tau}_{181p}$ [9, 15], we also included a measure of the linear combination of $A\beta_{1-42}$ and $p\text{-tau}_{181p}$ that has not been previously tested on their predictive utility for conversion to AD. According to published ADNI proposed CSF cutoffs values [16], we classified the subjects based on high or positive (>23 pg/mL) and low or negative (<23 pg/mL) $p\text{-tau}_{181p}$ levels, and low or positive (<192 pg/mL) and high or negative (>192 pg/mL) $A\beta_{1-42}$ levels. We calculated a new ordinal variable with the combination of these cutoffs levels that yielded 4 levels: high AB and low p-tau codified as 1, high AB and high p-tau codified as 2, low AB and low p-tau codified as 3, and finally

low AB and high p-tau codified as 4. Subjects classified as having high AB (positive AB) and high p-tau (positive p-tau) were greater in the MCI converters group (82.1%) compared to non converters (53.1%) [$X^2= 16.27$, $p= 0.001$].

2.2.2. FDG-PET Acquisition and processing—A fluorodeoxyglucose positron emission tomography (FDG-PET) measure involving a voxelwise approach, the HCI, was used. This is a single measure intended to reflect the extent to which the pattern and magnitude of cerebral hypometabolism in an individual correspond to that in probable AD patients [10]. It also has been shown to be predictive of AD progression in MCI alone or in combination with hippocampal volume and episodic memory [17].

A specified reconstruction algorithm for each scanner type was implemented according to a standardized protocol to acquire FDG-PET data (www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml). All images were preprocessed by the ADNI PET coordinating center. The processing involved a voxelwise approach to analyze the data using statistical parametric mapping (SPM) performed by the Banner Alzheimer's Institute. Briefly, a hypometabolic convergence index (HCI) was calculated for each subject as detailed in Chen et al 2011 [10]; this index intended to characterize the extent of cerebral metabolic rate for glucose (CMRgl) reductions in each person compared to the reductions people with probable AD.

2.2.3. MRI Acquisition and processing—The scans used in this study were obtained from 1.5 Tesla scanners at different sites involved in ADNI with minor variations in the MRI protocol based on the specific configuration of each scanner. For the purpose of the present study, volumetric measures of the whole brain, ventricles, and left and right hippocampus, as well as cortical thickness measures of both left and right middle temporal, infero-temporal, and entorhinal cortex were investigated as derived by Freesurfer. Detailed description of MRI protocol and methods is available at ADNI webpage and upon request of the authors.

2.2.4. Cognitive Assessment—ADNI neuropsychological protocol followed guidelines to maximize inter-rater reliability and standard administration. The measures included in this study were the following: ADAS-Cog word recall, recognition, naming, number cancellation, and constructional and ideational praxis tests [18]; the Clock Drawing test [19]; Wechsler Memory Scale logical memory, and digit span test [20]; Rey auditory verbal learning test [21]; semantic category fluency test [22]; Trail Making test parts A and B [23], and Wechsler Adult Intelligence Scale digit symbol substitution test [24].

2.3. Statistical Analyses

Demographic, clinical, biomarkers and cognitive markers were compared between groups using t tests. Chi square tests were used to compare dichotomous variables.

To estimate the potential effects to predict conversion from MCI to AD of different sets of baseline variables we fitted logistic regression models following a stepwise procedure. The primary outcome of interest was change in the diagnostic (from MCI to AD) anytime during the 4 years of follow-up. We followed the same approach as on our previous study [2],

structured as follows. First, we tested the predictive validity, sensitivity and specificity of the best model we obtained in 2 years of follow-up but now applied to the 4 year follow-up data. Next, we performed sets of logistic regression analyses grouped in different clusters of variables: Demographic variables and genetic risk factor (APOE), CSF biomarkers, MRI biomarkers, PET-FDG HCI biomarker, and cognitive markers. This approach was undertaken to overcome the difference on sample sizes for each of the markers. From this set of clustered regressions models, we then selected only the significant predictors (selection of entry was set at $p < 0.05$) and combined them to obtain a final model of prediction of conversion to AD. Coefficient of determination in the form of pseudo- R^2 was used as a measure of the relative predictive power of the models. Predictive accuracy of the model was calculated using receiver operating characteristic curve (ROC) analysis. Note that age, sex and education were forced in all models.

3. Results

At baseline, 371 patients with MCI were included in the study. 53% were men and the age ranged from 55 to 90 years. All the MCI patients had completed cognitive assessment at baseline, 330 (88%) of them underwent successful MRI and 163 (44%) successful lumbar puncture.

Of the 371 patients diagnosed as MCI at baseline, 150 (40%) developed AD during follow-up (mean time until conversion 20.44 months; range 5.75–52.63). 168 MCI patients were stable at last follow-up (mean follow-up time 33.28 months; range 7.26–61.44).

Demographic, clinical characterization and APOE genotype status of the subjects is displayed in Table 1. Cognitive, brain morphometry, and CSF measures are displayed in Tables 2–3. The differences between MCI stable and conversion groups were similar to those found in our previous report comprising 2 years of follow-up [2]. Differences in almost all clinical staging variables, cognitive, brain morphometric variables, FDG-PET and CSF measures were found between both groups. Regarding cognitive measures, MCI non-converters showed similar performance than MCI converters only in digit span (Table 2). CSF measures, brain morphometry measure, and FDG-PET hypometabolic convergence index (Table 3), measure that was not included in our previous study, also detected differences between both MCI groups at baseline (except for ventricular volume that was similar between MCI non-converters and MCI converters).

3.1. Application of prior “best model”

By applying the best predictive model of conversion obtained at 2 years of follow-up (AVLT delayed, logical memory delayed and left middle temporal lobe thickness) to the current 4 years data, we obtained a pseudo- R^2 of 0.29 for the model (as compared to 0.34 at 2 years). The area under the curve was 0.77 (as compared to 0.80 at 2 years), with a percentage of cases classified correctly of 68%, a sensitivity of 66%, and a specificity of 70%, at a probability level of 0.50. The positive predictive value was 0.65 and the negative predictive value was 0.70.

3.2. Use of clustered regression models

In the clustered logistic regression models for the prediction of conversion from MCI to AD at 4 years, the findings suggested a very similar pattern to the 2-years follow-up findings (Table 4). APOE was a significant predictor of conversion in the demographic and genetic risk factor cluster. Among the cognitive markers, AVLT Trial 5 was a significant predictor of conversion (instead of AVLT delayed in the 2 year study); ADAS-Cog memory scale entered in the model as opposed to the 2 year's study where it did not predict conversion. The same brain cortical thickness measures as those found in the 2 years of follow-up (left middle temporal cortex thickness and left hippocampus volume) were still the best predictors of conversion at 4 years. Among the CSF biomarkers, T-tau/AB1-42 ratio remained predictor of conversion, as it was at 2 years, while the new classification variable of the linear combination of AB and p-tau did not reach predictive statistical significance. The HCI index of FDG-PET at baseline was also predictive of conversion to MCI in this univariate model.

When all the significant predictors of the clustered models (see “winners” model on Table 4) were entered in a single predictive logistic regression model, only the cognitive measures, AVLT Trial 5 and Clock test score, were found to best predict the development of AD in the MCI group of patients (pseudo-R²= 0.32). The receiver operating curve for this model showed an area under the curve of 0.78, a percentage of cases classified correctly of 78%, sensitivity of 58% and specificity of 74% at a cut-off point of 0.50 (Figure 1). The positive predictive value was 0.65 and the negative predictive value 0.67.

3.3. Contrast between old and new model of prediction

Last, we performed a chi-square test to compare the areas under the two different ROC curves. This statistical test takes into account both AUCs (prior and current model) and their respective standard errors ($\text{ChiSq} = (\text{AUC}_1 - \text{AUC}_2)^2 / (s_1^2 + s_2^2)$). The results showed both models were not statistically different ($X^2 = 0.35$; $p = 0.56$).

3.4. Patterns of decline in the different classes of markers

Figure 2 shows the difference (in effect size) between baseline and the different follow-ups for both groups of MCI (converters and stable). The group of MCI subjects who converted to AD showed greater decline in function (ES ranging from medium to large) as measured with the Functional Assessment Questionnaire (FAQ) [25], and in cognitive measures such as ADAS-Cog, AVLT Trial 5 and semantic fluency (with ES in the small to large range). Effect sizes for CSF and brain morphometry measures were small except for medium effect of middle temporal thickness, ventricular volume, left entorhinal cortex thickness, and HCI. The group of MCI that remained stable at follow-up had all effect sizes in the small range, except for FAQ and middle temporal thickness from both hemispheres that were medium (0.59 and 0.5 respectively).

4. Discussion

In this prospective study investigating a combination of different classes of biomarkers and cognitive markers in predicting development of AD in MCI patients during a follow-up

period of four years, two cognitive measures, a verbal episodic memory measure of learning (AVLT Trial 5), and a screening measure (Clock drawing test) assessing a combination of semantic knowledge, visual motor ability and executive function, were found to be the most significant predictors. Furthermore, these findings are strengthened by a complementary analysis where patterns of decline on the different markers showed that cognitive measures (plus a measure of function) had larger effect sizes in the MCI subgroup that progressed to AD.

In our previous study in the same sample, but with a shorter follow-up of 2 years, we found that two episodic delayed memory measures (plus left middle temporal thickness) were the variables that best predicted conversion to AD [2]. Application of this former predictive model to the current 4 year data, yielded an AUC= 0.77 (sensitivity is 66% and specificity is 70%). In comparison to our initial 2011 model, this reflected a decrease in specificity but an increase in sensitivity in the measures' ability to predict conversion to AD in 4 years of follow-up. Nevertheless, and critically, AUC and the pseudo-R² of our initial model at 2 years of follow-up were fully comparable to the new "winners" model at 4 years of follow-up (AUC= 0.78).

Several studies from ADNI, including our original study, have demonstrated that cognitive tests are robust predictors of MCI to AD conversion and HC-MCI discrimination [2–5, 17]. Studies conducted in other MCI populations (i.e., outside ADNI) have found results similar to ours when combining different classes of markers [26, 27]. Furthermore some findings place verbal episodic memory impairments (recall and learning) at least 5 years before dementia onset [28–30]. An interesting study has indicated that memory decline may be indicative of subclinical AD in otherwise healthy individuals as demonstrated by amyloid accumulation in PET-amyloid imaging [31]. Individual AUC for neuropsychological predictors (AVLT) was in some cases as high as for the combination models [27]. Nevertheless, studies outside ADNI have reported higher AUC probabilities as compared to our AUCs. Differential characteristics of the MCI samples under examination and different sampling procedures may have played role in this discrepancy, as other studies derived from ADNI have reported similar AUCs to ours when comparing MCI patients that converted to AD to those who remained stable [3].

There are several other issues that deserve comment. First, our new predictive model did not include any brain morphometry measure. Although left middle temporal lobe thickness and left hippocampus volume were significant predictors in the individual MRI model, they did not reach statistical significance when combined with the rest of the markers. One possible reason for this might be related to the inclusion of a glucose metabolism measure (FDG-PET), since when this biomarker was not modeled, both left middle temporal lobe thickness and left hippocampus volume (plus episodic memory), were significant predictors of conversion in the combined model (data not shown). Furthermore, a complementary analysis showed that middle temporal thickness and FDG-PET had greater decline along four years than the rest of the brain morphometric measures (See Figure 2). Hence, collinearity and sample size issues (subjects with valid measures on all the variables changed as different set of variables were fitted together) may have forced the exclusion of MRI measures of the final model.

A second issue relates to our CSF findings. When modeling only CSF measures, P-tau/AB1-42 ratio was found to be predictive of AD conversion; however this ratio did not demonstrate predictive significance when combined with other measures (MRI, FDG-PET and cognitive measures) in the final regression model. Therefore, in this MCI sample, CSF biomarkers at baseline did not have independent predictive utility when combined with other predictors, and additionally did not show significant decline through follow-up. It might be possible that this result is related to the stage in the progression of the underlying neuropathology in this particular MCI population [32] (i.e. CSF biomarkers have been proposed as more informative in very early preclinical states), or increased utility in longer follow-ups [33], making these measures perhaps more suitable to identify healthy subjects at risk of future AD development.. However, our results suggest that cognitive markers may be equally if not more effective as predictors in our study. As opposed to our methods, pre-clinical CSF studies generally do not directly compare CSF and cognitive markers. Additionally, it has also been claimed that Ab associated brain volume loss [15] and clinical decline [9] occurs only in the presence of elevated p-tau. However, our findings do not point toward strong predictive ability of ptau/AB linear combination on AD progression in MCI.

Third, it is important to note that the number of subjects included in our regression models decreased when predictive variables were progressively estimated together, given that fewer subjects underwent lumbar punctures, compared to MRI or cognitive assessment; this fact may have restricted our ability to adequately compare different clusters of markers in simultaneous combination. Our approach to overcome this issue was clustering set of similar markers into separate regression analyses, hence maximizing sample size on each model, and finally aggregate the resulting significant measures (“winners”) into a final predictive model,. Also, we acknowledge that our findings may not be fully generalizable to other studies outside ADNI.

Fourth, another factor that could have influenced our findings is related to age of the subjects studied. MRI and cognition have been found to remain informative in both older and younger patients (as subjects included in our study), unlike CSF biomarkers that only are predictive of subsequent AD development in younger individuals [34]. As such biological and cognitive markers may have different roles at various points in the development of AD, i.e. can be differentially sensitive to changes at different stages of the disease [35].

Finally, as our complementary effect size analysis indicated, function as measured by the FAQ, showed the highest decline through four years in the MCI converters subgroup. However, we did not include it in the predictive models because doing so would create a tautology (i.e., function is used to distinguish the MCI and AD diagnoses). Nevertheless, empirically, it is a strong predictor of conversion.

In summary, cognitive markers were still predictive of conversion to AD in a MCI population at four years of follow-up, as they were found to be at two years of follow-up. This set of findings highlights the importance of cognitive measures, even those derived from basic clinical neuropsychological tests, in their predictive utility for MCI to AD progression.

Acknowledgments

This study was supported by the Litwin-Zucker Research Center of the Feinstein Institute for Medical Research (North Shore-LIJ Health System) and National Institutes of Health (RO1 AG038734 to TEG).

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California San Diego. ADNI data are disseminated by the Laboratory for Neuro-Imaging at the University of California, Los Angeles. Dr. Davies has received research support from and served as a consultant to Applied Neurosolutions. Dr. Goldberg receives royalties for the use of the Brief Assessment of Cognition in Schizophrenia (BACS) in clinical trials.

References

1. Ferri CP, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2005; 366(9503): 2112–7. [PubMed: 16360788]
2. Gomar JJ, et al. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. *Arch Gen Psychiatry*. 2011; 68(9):961–9. [PubMed: 21893661]
3. Ewers M, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. *Neurobiol Aging*. 2012; 33(7):1203–1214 e2. [PubMed: 21159408]
4. Heister D, et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. *Neurology*. 2011; 77(17):1619–28. [PubMed: 21998317]
5. Jedynak BM, et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort. *Neuroimage*. 2012; 63(3): 1478–86. [PubMed: 22885136]
6. Snyder PJ. The retooling of old cognitive tests as an interim step on the path to validating a next generation of neuropsychological paradigms and assays. *Alzheimers Dement*. 2013; 9(1 Suppl):S1–3. [PubMed: 23391005]
7. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. *Nature*. 2012; 483(7391):531–3. [PubMed: 22460880]
8. Begley CG. Six red flags for suspect work. *Nature*. 2013; 497(7450):433–4. [PubMed: 23698428]
9. Desikan RS, et al. Amyloid-beta--associated clinical decline occurs only in the presence of elevated P-tau. *Arch Neurol*. 2012; 69(6):709–13. [PubMed: 22529247]
10. Chen K, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. *Neuroimage*. 2011; 56(1):52–60. [PubMed: 21276856]
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975; 12(3):189–98. [PubMed: 1202204]
12. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993; 43(11):2412–4. [PubMed: 8232972]
13. Hansson O, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurol*. 2006; 5(3):228–34. [PubMed: 16488378]
14. Mattsson N, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA*. 2009; 302(4):385–93. [PubMed: 19622817]

15. Desikan RS, et al. Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. *Ann Neurol*. 2011; 70(4):657–61. [PubMed: 22002658]
16. Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Ann Neurol*. 2009; 65(4):403–13. [PubMed: 19296504]
17. Landau SM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology*. 2010; 75(3):230–8. [PubMed: 20592257]
18. Mohs RC, et al. Development of cognitive instruments for use in clinical trials of antimentia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. *Alzheimer Dis Assoc Disord*. 1997; 11(Suppl 2):S13–21. [PubMed: 9236948]
19. Goodglass, H.; Kaplan, E. *The assessment of aphasia and related disorders* 1983. Philadelphia: Lea & Febiger;
20. Wechsler, D. *Wechsler Memory Scale-Revised*. San Antonio, TX: The Psychological Corporation; 1987.
21. Rey, A. *L'examen clinique en psychologie*. Paris: Presses Universitaires de France; 1964.
22. Morris JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology*. 1989; 39(9): 1159–65. [PubMed: 2771064]
23. Reitan, RM.; Wolfson, D. *The Halstead-Reitan Neuropsychological Test Battery*. Tucson: Neuropsychology Press; 1985.
24. Wechsler, D. *Wechsler Adult Intelligence Scale-Revised*. Sant Antonio, TX: The Psychological Corporation; 1981.
25. Pfeffer RI, et al. Measurement of functional activities in older adults in the community. *J Gerontol*. 1982; 37(3):323–9. [PubMed: 7069156]
26. Devanand DP, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. *Biol Psychiatry*. 2008; 64(10):871–9. [PubMed: 18723162]
27. Eckerstrom C, et al. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. *J Alzheimers Dis*. 2013; 36(3):421–31. [PubMed: 23635408]
28. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. *Nat Med*. 2004; 10(Suppl):S34–41. [PubMed: 15298007]
29. Tierney MC, et al. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. *Neurology*. 2005; 64(11):1853–9. [PubMed: 15955933]
30. Driscoll I, et al. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. *Ann Neurol*. 2006; 60(6):688–95. [PubMed: 17192929]
31. Darby DG, et al. Intraindividual cognitive decline using a brief computerized cognitive screening test. *Alzheimers Dement*. 2012; 8(2):95–104. [PubMed: 22404851]
32. Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011; 7(3):270–9. [PubMed: 21514249]
33. Buchhave P, et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Arch Gen Psychiatry*. 2012; 69(1): 98–106. [PubMed: 22213792]
34. Schmand B, Eikelenboom P, van Gool WA. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnesic mild cognitive impairment. *J Alzheimers Dis*. 2012; 29(3):641–8. [PubMed: 22297644]
35. Petersen RC. Alzheimer's disease: progress in prediction. *Lancet Neurol*. 2010; 9(1):4–5. [PubMed: 20083022]

RESEARCH IN CONTEXT

Systematic Review

Few studies combining several clinical, cognitive, and biological markers in the progression of Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) have been carried out. We searched PubMed for published studies of combined predictive utility of different markers on the progression from MCI to AD, and conducted our analyses in ADNI.

Interpretation

Our findings highlight the importance of cognitive measures on the detection of pre-clinical AD and prediction of progression from MCI to AD both over shorter and longer time periods. Cognitive markers perform as robustly, if not more so, than biomarkers in unbiased predictive models of the development of AD.

Future Directions

Future studies should compare all classes of markers on integrative models of prediction comprising longer follow-ups in at risk groups. Development of novel and sensitive measures of episodic memory may be an economical, safe, and empirically promising approach to capture changes in prodromal AD and perhaps preclinical AD.




Figure 1. Receiver Operating Curve (ROC) of the “winners” logistic regression model
 Receiver Operating Curve of significant predictors in the “winners” logistic regression model. The red line indicates the three demographic variables (age, gender and education) forced into the model; the green line indicates the first variable to enter the model, Auditory Verbal Learning Test Trial 5 with an Area Under the Curve (AUC) of 0.72; the blue line indicates the last variable to enter the model, Clock test score with an AUC of 0.78.




Figure 2. Patterns of decline of the different classes of markers

Panel 1 shows the effect sizes for the difference in cognitive and functioning scores between baseline and each one of the follow-ups from months 12 to 48 (except for ADAS-Cog test from month 12 to 36): 1A for the MCI group that converted to AD, and 1B for the MCI group that remained stable. Panel 2 shows effect sizes in MRI morphometry, FDG-PET HCl, and CSF biomarkers between baseline and each one of the follow-ups from months 12 to 36 (measures at month 48 were not available): 2A for the MCI group that converted to AD, and 2B for the MCI group that remained stable

Table 1

Baseline Demographic, Clinical, Functional and APOE Genotype Data

	MCI Non-converters (n= 168)	MCI Converters (n= 150)	Statistical Test	P Value
Sex (M/F)	109/59	90/60	$X^2 = 0.81$	0.37
Age, Mean (SD)	75.02 (7.51)	74.92 (7.03)	t316 = 0.12	0.90
Years of Education, Mean (SD)	15.77 (3.11)	15.63 (2.91)	t316 = 0.41	0.68
CDR sum of boxes, Mean (SD)	1.44 (0.78)	1.82 (0.93)	t316 = -3.95	<0.0001
MMSE, Mean (SD)	27.42 (1.72)	26.67 (1.71)	t316 = 3.86	<0.0001
APOE Status	E2E2= 0 E2E3= 12 E2E4= 3 E3E3= 82 E3E4= 56 E4E4= 15 E4 Carrier (42 %)	E2E2= 0 E2E3= 3 E2E4= 5 E3E3= 46 E3E4= 70 E4E4= 26 E4 Carrier (64 %)	$X^2 = 19.58$	<0.0001
FAQ Score, Mean (SD) *	2.54 (3.43)	5.36 (4.77)	t316 = -6.08	<0.0001

* Missing data for 2 MCI non converters;

MCI: Mild Cognitive Impairment; M: Male; F: Female; SD: Standard Deviation; CDR: Clinical Dementia Rating; MMSE: Mini-Mental State Examination; FAQ: Functional Assessment Questionnaire.

Table 2

Baseline Cognitive Status

	MCI Non- converters (n= 168)	MCI Converters (n= 150)	Statistical Test	P Value
ADAS Memory, Mean (SD)	14.00 (5.19)	17.69 (4.43)	t316 = -6.78	<0.0001
ADAS NonMemory ¹, Mean (SD)	2.71 (2.10)	3.72 (2.54)	t313 = -3.88	<0.0001
Logical Memory Immediate, Mean (SD)	7.73 (3.02)	6.42 (3.09)	t316 = 3.81	<0.0001
Logical Memory Delayed, Mean (SD)	4.47 (2.65)	2.84 (2.44)	t316 = 5.68	<0.0001
Clock Drawing Test, Mean (SD)	4.41 (0.81)	3.95 (1.08)	t316 = 4.31	<0.0001
AVLT Trial 5 ², Mean (SD)	8.24 (2.78)	6.43 (1.97)	t316 = 6.66	<0.0001
AVLT Delayed ³, Mean (SD)	3.72 (3.69)	1.57 (2.11)	t316 = 6.27	<0.0001
AVLT Recognition ⁴, Mean (SD)	10.41 (3.49)	8.69 (3.73)	t316 = 4.26	<0.0001
Category Fluency, Mean (SD)	13.91 (3.71)	12.74 (3.37)	t316 = 2.92	0.004
Trails A, Mean (SD)	40.39 (16.00)	48.68 (25.58)	t316 = -3.50	0.001
Trails B ⁵, Mean (SD)	115.04 (61.74)	151.30 (80.79)	t313 = -4.50	<0.0001
Digit Span, Mean (SD)	7.17 (1.80)	7.19 (1.67)	t316 = -0.09	0.93
Digit Symbol, Mean (SD)	39.52 (10.61)	34.41 (10.58)	t316 = 4.30	<0.0001

¹ Missing data for 1 MCI non converter and 2 MCI converters;

² Missing data for 2 healthy subjects;

³ Missing data for 1 healthy subject;

⁴ Missing data for 1 healthy subject;

⁵ Missing data for 3 MCI non converters;

FDG-PET: Fluorodeoxyglucose-positron emission tomography; HCI: Hypometabolic convergence index.

Table 3

Baseline Brain Morphometry and CSF Biomarkers

Brain Morphometry				
	MCI Non- converters (n=152)	MCI Converters (n=132)	Statistical Test	P value
Whole-brain, Mean (SD) ¹	1004472 (103950)	979445 (115133)	t282 = 1.92	0.06
Ventricles, Mean (SD) ¹	43850 (22151)	46619 (18878)	t282 = -1.12	0.26
Left Hippocampus, Mean (SD) ¹	3236 (503)	2987 (493)	t282 = 4.21	<0.0001
Right Hippocampus, Mean (SD) ¹	3424 (542)	3152 (568)	t282 = 4.13	<0.0001
Left Middle Temporal cortical thickness, Mean (SD) ²	2.49 (0.19)	2.35 (0.21)	t282 = 5.79	<0.0001
Right Middle Temporal cortical thickness, Mean (SD) ²	2.54 (0.18)	2.41 (0.23)	t282 = 5.20	<0.0001
Left entorhinal cortical thickness, Mean (SD) ²	2.96 (0.51)	2.76 (0.45)	t282 = 3.54	<0.0001
Right entorhinal cortical thickness, Mean (SD) ²	3.09 (0.53)	2.86 (0.51)	t282 = 3.72	<0.0001

FDG-PET				
	MCI Non- converters (n= 88)	MCI Converters (n= 74)	Statistical Test	P value
HCI, Mean (SD)	7.14 (3.47)	9.75 (3.88)	t160= -4.52	<0.0001

CSF Biomarkers				
	MCI Non- converters (n= 82)	MCI Converters (n= 84)	Statistical Test	P value
AB, Mean (SD)	5.09 (0.35)	4.94 (0.26)	t164 = 3.13	0.002
Total Tau, Mean (SD)	4.38 (0.52) ³	4.61 (0.40)	t164 = -3.06	0.003
P Tau, Mean (SD)	3.33 (0.52)	3.58 (0.42) ⁴	t164 = -3.46	0.001
Total Tau/AB, Mean (SD)	-0.71 (0.74) ³	-0.34 (0.54)	t164 = -3.64	<0.0001
P Tau/AB, Mean (SD)	-1.76 (0.77)	-1.36 (0.57)	t164 = -3.81	<0.0001

¹ Measured in mm³;

² Measured in mm;

³ N=79, 3 subjects had AB and had not t-tau;

⁴ N=85, 1 subject had p-tau and had not t-tau and AB.

Table 4

Clustered logistic regression models of conversion over 4 years

	OR (95% CI)	R ² /p
Demographics & APOE (X²= 15.07/p=0.005; AUC=0.62)		
APOE	2.41 (1.50–3.91)	R ² =0.07/p=0.0003
Cognitive Markers (X²= 84.23/p<0.0001; AUC=0.78)		
AVLT Trial 5	0.83 (0.73–0.95)	R ² =0.19/p<0.0001
Logical Memory delayed	0.83 (0.74–0.93)	R ² =0.05/p=0.0003
Clock Drawing Test	0.65 (0.48–0.86)	R ² =0.03/p=0.001
Trail Making Test, Part A	1.02 (1.00–1.03)	R ² =0.03/p=0.01
ADAS-Cog Memory	1.08 (1.01–1.15)	R ² =0.02/p=0.02
Brain Morphometric Measures (X²= 50.45/p<0.0001; AUC=0.74)		
Left Middle Temporal Lobe Thickness	0.03 (0.007–0.12)	R ² =0.16/p<0.0001
Left Hippocampus Volume	0.999 (0.998–0.999)	R ² =0.06/p=0.0002
FDG-PET Measure (X²= 17.96/p<0.0001; AUC=0.70)		
HCI	1.21 (1.10–1.34)	R ² =0.15/p=0.0007
CSF Biomarkers (X²= 14.66/p=0.005; AUC=0.66)		
P-tau/Aβ Ratio	2.34 (1.45–3.91)	R ² =0.12/p=0.0005
“Winners” Model, i.e., including only previous significant measures (X²= 19.64/p=0.001; AUC=0.78)		
AVLT Trial 5	0.65 (0.47–0.85)	R ² =0.20/p=0.001
Clock Drawing Test	0.43 (0.21–0.85)	R ² =0.12/p=0.006

OR: Odds Ratio; CI: Confidence Interval; R²: Pseudo-R/square; p: Significance Level; AUC: Area Under the Curve; AVLT: Auditory Verbal Learning Test; ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive; CSF: Cerebrospinal Fluid.